To unlock the vast potential of chimeric antigen receptor (CAR) T cell therapy, it is essential to explore the identification and surveillance of biomarkers linked to T cell activation and associated cytokine release syndrome (CRS).
Bio-Techne uses cookies to provide you with a great website experience. By continuing to use this website you acknowledge this and agree to our cookie policy. Learn more.
